PERTH, Australia – Sydney-based Immutep Ltd. unveiled new data for its phase I immunotherapy study that showed a long-lasting and durable response and an overall response rate of 61 percent in a melanoma study combining its lead immunotherapy with Merck's anti-PD-1 therapy Keytruda (pembrolizumab).
PERTH, Australia – In response to industry comments, Australia's Therapeutic Goods Administration (TGA) is getting ready to implement a new fee structure for drug GMP inspections.
PERTH, Australia – Sydney-based Minomic International Ltd.'s Micheck prostate cancer diagnostic was more than twice as specific in screening for prostate cancer than the standard of care prostate specific antigen (PSA) screening technology, a recent clinical trial showed. The Micheck diagnostic met both primary endpoints in a U.S. multicenter trial in 384 patients. The trial was a prospective, non-randomized case-control study, with a primary endpoint of detecting prostate cancer versus no cancer, and a secondary endpoint of differentiating between aggressive and non-aggressive cancer.
PERTH, Australia – Industry stakeholders praised Australia's federal budget for 2018-2019, released late last week, because the government said it was seeing results from investments pumped into the medical technology and pharmaceuticals sector, and it will continue to invest more.
PERTH, Australia – Industry stakeholders praised Australia's federal budget for 2018-2019, released late last week, because the government said it was seeing results from investments pumped into the medical technology and pharmaceuticals sector, and it will continue to invest more.
